H. Michael Shepard, USA

Chief Scientist, Frontiers in Therapeutics Research Center and Changjiang Distinguished Professor,

Shanghai Jiaotong University-Ruijin Hospital

Professor Michael Shepard is a globally recognized innovator in biotechnology and a pioneering figure in cancer research. As the Chief Scientist of the Frontiers in Therapeutics Research Center, an Oncology Biology Consultant, and a Changjiang Distinguished Professor, he has made transformative contributions to the field. One of the key inventors of Herceptin (Trastuzumab), a groundbreaking therapy for HER2-positive breast cancer, his work has benefited over 500,000 patients worldwide. Professor Shepard also pioneered the concept of “pan-HER” inhibition, Enzyme Catalyzed Therapeutics (ECTA), and introduced the first adenoviral gene therapy into clinical trials, resulting in the recent approval of adstiladrin, a non-replicating adenoviral gene therapy for high-risk bladder cancer. Currently, he is expanding his successful cancer treatment models to address inflammation and autoimmune diseases. His achievements have earned him prestigious awards, including the 2019 Lasker~DeBakey Clinical Medical Research Award and the 2007 Warren Alpert Prize. With over 50 patents in biotherapeutics and diagnostics and numerous publications in peer-reviewed journals, Professor Shepard is also deeply committed to mentoring young scientists and inspiring innovation through lectures and collaborations. His dedication to advancing science and nurturing the next generation of researchers underscores his leadership in both research and education through his work at Ruijin Hospital, the Damon Runyon Cancer Research Foundation and the Knight Institute, Oregon Health Sciences University.

Lectures：
Plenary Session 2: Keynote Session | The Future of Antibody Therapeutics